Word

CSL VIFOR

Status

Pending

Status Code

686

Status Date

Tuesday, April 2, 2024

Serial Number

79376320

Mark Type

4000

Filing Date

Thursday, March 16, 2023

Published for Opposition

Tuesday, April 2, 2024

Trademark Owner History

Vifor (International) AG (Vifor (International) Ltd.) (Vifor (International) Inc.) - Owner At Publication

Classifications

41 Education services, namely, medical training and teaching; health training, namely, training in the use and operation of medical imaging apparatus; consultancy services relating to training and education in the field of medical training; provision of education services, namely, providing classes, courses, conferences, workshops and seminars in the field of healthcare via an online forum; provision of training and education courses in the field of healthcare; publication of educational material being books, journals and manuals in the medical field; dissemination of printed educational material of others in the field of medicine; entertainment via weblog, namely, providing a website featuring blogs featuring healthcare and medicine; open access publishing services, namely, electronic publication of information on a wide range of topics in healthcare and medicine by publication of electronic texts, and journals online and over a global computer network; entertainment services, namely, online provision of non-downloadable virtual goods being toys for use in virtual environments created for entertainment purposes; providing online electronic publications, not downloadable in the nature of books, articles, and newsletters in the field of medicine

40 Treatment of waste materials; treatment of biological products through biomanufacturing for others, namely, custom manufacturing and fractionation of blood to manufacture pharmaceuticals to the order and requirements of a customer using biological organisms in the manufacturing process; treatment and transformation of reagents and ancillary products through custom manufacture of medical reagents for immunohaematology laboratories for third parties to order; processing of human blood plasma, namely, removing whole blood and separating red blood cells from plasma for the custom manufacture of medicines; treatment of human blood and plasma for the custom manufacture of pharmaceuticals; fractionation of human blood and plasma for the custom manufacture of medicines; custom manufacturing of human blood and plasma to the order and requirements of a customer

9 Downloadable software for providing medical test results; downloadable application software for providing medical test results; downloadable software applications for providing medical test results; downloadable computer software and programs for providing medical test results; electronic or recorded multimedia publications, namely, downloadable electronic publications in the nature of articles and newsletters in the field of blood disorders; downloadable publications in electronic form in the nature of articles and newsletters in the field of blood disorders; electronic audiovisual teaching materials, namely, audiovisual recordings featuring educational healthcare information; printed publications in electronically readable or downloadable form, namely, downloadable e-books in the field of healthcare; electronic publications downloadable from the internet or from any other communication network, namely, downloadable written articles in the field of medicine; educational materials in the form of computer software and programs, and applications for use on mobile telephones, namely, downloadable educational mobile applications for accessing and reading medical news; educational materials in the form of pre-recorded media being flash drives featuring healthcare information and medical news; downloadable software that can represent goods virtually, namely, downloadable virtual reality software for medical teaching; downloadable digital multimedia files containing text, videos, and audio recordings relating to healthcare authenticated by non-fungible tokens (NFTs)

5 Pharmaceutical preparations and substances for the treatment of kidney diseases, blood conditions, and transplant conditions; Pharmaceutical preparations and substances for the treatment of iron deficiencies, anemia, and nephrology; blood plasma; blood products, namely, blood for medical purposes; products derived from blood, namely, cord blood for medical purposes; products derived from recombinant DNA technology, namely, human recombinant insulin and hormones; vaccines; colostral antibodies for medical purposes; monoclonal antibodies for medical purposes; reagent red-blood cells for medical use; test kits, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; diagnostic products, namely, medical diagnostic reagents and diagnostic preparations for medical purposes; blood products, namely, blood plasma; medical and veterinary test kits, namely, drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids; influenza vaccines; adjuvants for medical purposes and antigens being synthetic peptides for the treatment of blood disorders; pharmaceutical preparations and substances for the treatment and prevention of blood or bleeding disorders; blood products, namely, blood plasma, reagent blood cells for medical use; products derived from blood and products derived from recombinant DNA technology, namely, colostral antibodies being immunoglobulins, human albumin, blood clotting factor preparations, plasma volume expanders, blood proteins for therapeutic medical use; serums for medical use, namely, medicated antivenom serum for treatment of venomous bites and stings; medicated serums for the treatment of blood or bleeding disorders; test kits, namely, in-vitro diagnostic reagent test kits comprised of medical diagnostic reagents for use in detecting cell-mediated immune response for disease testing; pharmaceutical preparations and substances, namely, medical diagnostic rhesus factor-D reagents for the detection of specific antigens and for use in blood typing for medical use; pharmaceutical preparations, namely, reagent red blood cells used to detect antibodies or immunoglobulin G subtypes for medical use; pharmaceutical preparations, namely, monoclonal and polyclonal antibodies for medical purposes; pharmaceutical preparations, namely, reagents for medical or clinical medical use for the typing and detection of specific blood cells, and the detection of relevant complement components and immunoglobulin subtypes; pharmaceutical and veterinary preparations for use in oncology and for treating diabetes; pharmaceutical and veterinary preparations for use in transplantation, transplantation rejection therapy and transplantation-associated diseases and conditions; pharmaceutical and veterinary preparations comprising stem cells for medical or veterinary use; pharmaceutical and veterinary preparations for use in treatment and prevention of dialysis-associated diseases, conditions and complications; pharmaceutical and veterinary preparations for use in preserving and improving renal function, for the treatment and prevention of acute kidney injury, for the treatment and prevention of chronic kidney diseases and associated complications; pharmaceutical and veterinary preparations for the treatment and prevention of cardiac, cardiovascular, circulatory, renal system, kidney, cardio-renal, immune system, gastroenterological, gastrointestinal, stomach, dermatological, hematological, bone, respiratory, genetic, allergic, inflammation, infectious, pain, central nervous system, endocrinology, hormonal, muscular, rheumatic, ocular and metabolic diseases and disorders; pharmaceutical and veterinary preparations used as immune system stimulators for the treatment and prevention of chronic kidney diseases; pharmaceutical preparations for the treatment and prevention of mineral deficiencies and mineral overload as well as diseases and conditions associated with mineral deficiencies or mineral overload; pharmaceutical preparations for the treatment and prevention of metal deficiencies and metal overload as well as diseases and conditions associated with metal deficiencies or metal overload; pharmaceutical preparations for the treatment and prevention of vitamin deficiencies and vitamin overload as well as diseases and conditions associated with vitamin deficiencies or vitamin overload, vitamin and mineral supplements, vitamin preparations and mineral preparations for medical use

3 Cleaning, polishing and abrasive preparations; degreasers, other than for use in manufacturing processes

1 Chemical reagents for non-medical purposes; biological reagents for scientific and research use; cell cultures for scientific and research use and cell culture media for scientific and research use; laboratory and scientific test kits, namely, testing kits containing peptide substrates used in analyzing and detecting certain toxins for clinical or medical laboratory use and chemical test kits for chemical or biological analysis for laboratory or research use; chemical preparations for scientific and industrial use, other than for medical or veterinary use; diagnostic agents and testing means, namely, diagnostic reagents and preparations, except for medical or veterinary use; chemical and biological reagents for non-medical scientific and research use; chemical and biological research reagents for industrial use for anti-body screening, blood grouping, and for the typing and detection of specific blood cells, determining the presence of antigens on blood cells, and the detection of relevant complement compounds and immunoglobulin subtypes, all of the foregoing for non-medical purposes; chemical test kits for the detection of specific blood cells, determining the presence of antigens on blood cells, and the detection of relevant complement compounds and immunoglobulin subtypes for laboratory or research purposes; chemical preparations for industrial use for anti-body screening, blood grouping, and the typing and detection of specific blood cells

44 Medical services; medical information services provided via the Internet; health care services; Internet-based health care information services; medical diagnostic services, namely, medical testing and analysis relating to the diagnosis and treatment of disease; patient support services, namely, reporting of consumer authorized clinical testing results directly to the patient; medical, pharmaceutical and blood product consultancy services to provide medical consultation in the selection and use of medical, pharmaceutical and blood products; medical advisory services; providing medical information concerning pharmaceuticals, medical products and blood products; blood bank services; health centre services through operating blood and plasma collection centres; medical testing for diagnostic or treatment purposes and medical screening services; medical testing of human blood plasma for medical diagnostic or treatment purposes; medical services for the collection, processing and testing of human blood and plasma; providing medical information concerning blood products; providing medical information concerning vaccines, antivenoms and immunohaematology products being diagnostic reagents; patient support services, namely, providing patient medical information where patients can enquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community creation purposes via an Internet-based database

10 Surgical apparatus and instruments; medical apparatus and instruments for monitoring blood properties and respiratory events; implantable medical devices, namely, intravascular implants comprised of artificial material; analysis apparatus and instruments for medical use, namely, medical diagnostic instruments for the analysis of body fluids and medical instrument for cardiovascular diagnostics; medical apparatus and instruments, namely, medical apparatus and instruments for monitoring vital signs, blood properties and respiratory events; medical apparatus and instruments for monitoring blood oxygen saturation, blood gas concentrations, and vital signs; test kits, namely, diagnostic kits consisting primarily of probes, buffers and reagents for use in microbial testing

42 Scientific and technological services, namely, scientific research, analysis, testing in the field of medicine; scientific research and development; pharmaceutical research and development; medical research and development in the field of blood disorders; blood product research and development services; clinical research in the field of medical uses of blood; provision of testing facilities for testing of pharmaceuticals; rental of research facilities for conducting scientific research in the field of medicine; laboratory analysis and research in the field of pharmaceuticals; scientific research consulting through technical planning of scientific research projects of others; technical consulting in the field of pharmaceutical studies through preparation of technical studies, technical reports, scientific reports; medical research through conducting of scientific and medical research projects and through preparation of reports relating to scientific and medical research; provision of medical research services and facilities, medical research through provision of research results, information and outcomes; provision of medical research information relating to all the aforementioned services; medical research consultancy services relating to all the aforementioned services; provision of medical research information relating to the aforementioned services over a global computer network; medical research laboratory services through providing scientific research studies and scientific testing of human blood plasma for safety and quality screening; medical research laboratory services regarding human blood plasma for medical diagnostics; hosting of blogs

Trademark Events

Apr 2, 2024

Official Gazette Publication Confirmation E-Mailed

Apr 2, 2024

Published For Opposition

Mar 27, 2024

Notification Of Possible Opposition Sent To Ib

Mar 27, 2024

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Mar 13, 2024

Notification Of Notice Of Publication E-Mailed

Feb 29, 2024

Approved For Pub - Principal Register

Feb 29, 2024

Examiner's Amendment Entered

Feb 29, 2024

Notification Of Examiners Amendment E-Mailed

Feb 29, 2024

Examiners Amendment E-Mailed

Feb 29, 2024

Examiners Amendment -Written

Feb 26, 2024

Teas/Email Correspondence Entered

Feb 26, 2024

Correspondence Received In Law Office

Feb 26, 2024

Teas Response To Office Action Received

Nov 28, 2023

Refusal Processed By Ib

Nov 7, 2023

Non-Final Action Mailed - Refusal Sent To Ib

Nov 7, 2023

Refusal Processed By Mpu

Nov 7, 2023

Non-Final Action (Ib Refusal) Prepared For Review

Nov 6, 2023

Non-Final Action Written

Nov 2, 2023

Assigned To Examiner

Oct 23, 2023

Correction From Ib Entered - No Review Required

Sep 24, 2023

Correction Transaction Received From Ib

Aug 29, 2023

Application Filing Receipt Mailed

Aug 24, 2023

New Application Office Supplied Data Entered

Aug 18, 2023

Limitation From Original Application Entered

Aug 10, 2023

Sn Assigned For Sect 66a Appl From Ib